ArticleJournal of the National Cancer Institute2026
Methylation signatures distinguish non-small cell lung cancer subtypes and are associated with survival in smokers with lung squamous cell carcinoma.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionLung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the 2 major histologic subtypes of non-small cell lung cancer and differ in prognosis, biological behavior, and molecular characteristics. Although aberrant DNA methylation has been implicated in lung cancer and patient survival, systematic investigations of subtype-specific methylation signatures distinguishing these subtypes remain limited.
methodsWe identified DNA methylation signatures that distinguish LUSC from LUAD and evaluated their associations with survival among ever-smokers using data from The Cancer Genome Atlas, with independent validation in the CURELUNG cohort. Survival analyses assessed associations between a methylation-based score and patient survival. Integrative analyses incorporating mRNA expression, global proteomic profiles, and transcription factor (TF) motifs enrichment were performed to explore potential regulatory features associated with the identified methylation markers.
resultsEleven differentially methylated CpG sites distinguished LUSC and LUAD and demonstrated high classification accuracy in an independent validation cohort. Among LUSC cases, lower methylation scores (below the median) were associated with a 2.7-fold increased risk of mortality during the first 2 years of follow-up based on piecewise Cox regression models. Integrative analyses revealed subtype-specific differences in CALML3 expression and enrichment of TF binding motifs near the identified signatures, particularly C2H2 zinc-finger motifs.
conclusionThis study identified a subtype-specific DNA methylation signature that robustly distinguishes LUAD and LUSC and is associated with early survival among ever-smokers with LUSC. These findings highlight biologically meaningful epigenetic patterns that may contribute to histology-specific tumor behavior and provide a foundation for future mechanistic and biomarker development studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.